Stockscreener 앱 받기
14.63
10.02%
-1.63
시간 외 거래:
14.63
Aardvark Therapeutics Inc 주식(AARD)의 최신 뉴스
Will Aardvark Therapeutics Inc. stock outperform international peersEarnings Recap Report & Long-Term Safe Investment Ideas - newser.com
What’s the recovery path for long term holders of Aardvark Therapeutics Inc.Risk Management & Low Risk High Win Rate Picks - newser.com
Using Ichimoku Cloud for Aardvark Therapeutics Inc. technicalsJuly 2025 PostEarnings & Weekly Chart Analysis and Guides - newser.com
Aardvark Therapeutics Inc. stock volume spike explainedTake Profit & Weekly Watchlist of Top Performers - newser.com
Is Aardvark Therapeutics Inc. stock ready for breakout2025 Key Highlights & Detailed Earnings Play Strategies - newser.com
What data driven models say about Aardvark Therapeutics Inc.’s future2025 Key Highlights & AI Forecast for Swing Trade Picks - newser.com
How risky is Aardvark Therapeutics Inc. stock nowMarket Volume Report & High Accuracy Trade Signal Alerts - newser.com
Using portfolio simulators with Aardvark Therapeutics Inc. includedJuly 2025 Closing Moves & Long-Term Capital Growth Strategies - newser.com
Aardvark Therapeutics Aligns with FDA on Trial Amendment - TipRanks
Aardvark Therapeutics (NASDAQ:AARD) Receives "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome - The Manila Times
Phase 3 HERO Expanded to Ages 10+ — Aardvark Aligns with FDA on ARD-101 Trial; Readout Q3 2026 - Stock Titan
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Aardvark Therapeutics Inc a good long term investmentPrice Action Analysis & Explosive Capital Growth - earlytimes.in
Insiders Of Aardvark Therapeutics Reap Rewards After Their Investment Jumps Another US$275k - 富途牛牛
Insiders Rewarded With US$275k Addition To Investment As Aardvark Therapeutics Stock Hits US$349m - simplywall.st
Using economic indicators to assess Aardvark Therapeutics Inc. potentialQuarterly Market Summary & Verified Momentum Watchlists - newser.com
What does recent volatility data suggest for Aardvark Therapeutics Inc.Trade Risk Report & Community Verified Swing Trade Signals - newser.com
Analyzing drawdowns of Aardvark Therapeutics Inc. with statistical tools2025 Short Interest & Real-Time Volume Spike Alerts - newser.com
H.C. Wainwright Maintains Aardvark Therapeutics(AARD.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Short Interest Update - Defense World
Aardvark Therapeutics Inc. stock trend forecastWeekly Risk Report & Accurate Technical Buy Alerts - newser.com
Should you wait for a breakout in Aardvark Therapeutics Inc.Short Setup & Real-Time Chart Breakout Alerts - newser.com
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Jones Trading - Defense World
Jones Trading Initiates Coverage of Aardvark Therapeutics (AARD) with Buy Recommendation - Nasdaq
This Coinbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
JonesTrading Initiates Aardvark Therapeutics(AARD.US) With Buy Rating, Announces Target Price $33 - 富途牛牛
Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics - TipRanks
Aardvark stock slides 11% following $94M IPO - MSN
Jones Trading initiates coverage on Aardvark Therapeutics stock with Buy rating - Investing.com Nigeria
Goldman Sachs Group Inc. Purchases New Shares in Aardvark Therapeutics, Inc. $AARD - Defense World
1.11%
자본화:
|
볼륨(24시간):